J&J Risperdal Sales Climb; Pricing Relative To Invega Depends On Dose
Executive Summary
Johnson & Johnson's blockbuster atypical antipsychotic Risperdal (risperidone) shows no signs of slowing growth a year before the drug is scheduled to lose patent protection